Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TCR-gene-transduced autologous lymphocytes - Takara Bio

Next Previous
Drug Profile

Research programme: TCR-gene-transduced autologous lymphocytes - Takara Bio

Alternative Names: RetroNectin® gene therapy - Takara Bio; RetroNectin® TCR gene therapy - Takara Bio; TCR gene therapy - Takara Bio; TCR gene transduced autologous lymphocytes - Takara Bio

Latest Information Update: 16 Apr 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takara Bio
  • Developer Mie University; National Cancer Institute (USA); Takara Bio
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 15 Mar 2019 Takara Bio submits Drug Master File to the US FDA for the liquid formulation of RetroNectin GMP grade
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top